Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 16/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2723304 | 0.93 | PIK3CD (0.68) | PIK3CDPIK3CGMAPT | |
| SCHEMBL4288631 | 0.92 | PIK3CG (0.59) | PIK3CDPIK3CGMAPT | |
| SCHEMBL4291785 | 0.90 | PIK3CD (0.64) | PIK3CDPIK3CGMAPTSLC40A1 | |
| SCHEMBL4302115 | 0.90 | PIK3CD (0.70) | PIK3CDPIK3CGMAPTSLC40A1 | |
| SCHEMBL2721975 | 0.90 | PIK3CG (0.63) | PIK3CDPIK3CGMAPT | |
| SCHEMBL4287828 | 0.89 | PIK3CD (0.62) | PIK3CDPIK3CGMAPT | |
| SCHEMBL10044550 | 0.88 | PIK3CG (0.53) | PIK3CDPIK3CGMAPT | |
| SCHEMBL2722453 | 0.87 | PIK3CG (0.63) | PIK3CDPIK3CGMAPT | |
| SCHEMBL15180098 | 0.86 | PIK3CG (0.51) | PIK3CDPIK3CGMAPT | |
| SCHEMBL2722050 | 0.86 | PIK3CG (0.55) | PIK3CDPIK3CGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630129-B1 | QUINOXALINE DERIVATES | MERCK PATENT GMBH (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-8895559-B2 | Quinoxalines derivatives and pharmaceutical compositions and kits | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8895559-B2 | Quinoxalines derivatives and pharmaceutical compositions and kits | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-20130217670-A1 | QUINOXALINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217670-A1 | QUINOXALINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| US-20130211076-A1 | Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides | MERCK SERONO S.A. GENEVA (CH) | 2013-08-15 | — | — | US | disclosed |
| US-20130211076-A1 | Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides | MERCK SERONO S.A. GENEVA (CH) | 2013-08-15 | — | — | US | disclosed |
| WO-2012052420-A1 | METHOD FOR PREPARING SUBSTITUTED N-(3-AMINO-QUINOXALIN-2-YL)-SULFONAMIDES AND THEIR INTERMEDIATES N-(3-CHLORO-QUINOXALIN-2-YL)SULFONAMIDES | MERCK SERONO S.A. GENEVA (CH) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012052102-A1 | QUINOXALINE DERIVATES | MERCK PATENT GMBH (DE) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217670-A1 | QUINOXALINE DERIVATIVES | PIK3R5, NQO2, PIK3R1 | PIK3CD 14/4885PIK3CG 8/4885MAPT 4120/4885 |
| US-20130211076-A1 | Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides | STS, NQO2, ASNS | PIK3CD 2887/4885PIK3CG 2294/4885MAPT 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.